angiotensin-converting enzyme inhibitor + adrenergic receptor binder + adrenal cortical hormone + tripterygium wilfordii polyglycosidium + immunosuppressant

This is a combination regimen containing five distinct active pharmacological classes: - **Angiotensin-converting enzyme (ACE) inhibitor**: Blocks the conversion of angiotensin I to angiotensin II, leading to vasodilation, reduced aldosterone secretion, and lower blood pressure. Commonly used in hypertension, heart failure, and kidney disease[1][4][10]. - **Adrenergic receptor binder**: Typically refers to beta-adrenergic receptor blockers, which antagonize adrenergic signaling, reducing heart rate and contractility; also used to lower blood pressure and treat cardiac conditions[7]. - **Adrenal cortical hormone**: Refers to corticosteroids such as prednisone or hydrocortisone, which act as anti-inflammatory and immunosuppressive agents mainly by modulating gene transcription and protein synthesis[5][8][9]. - **Tripterygium wilfordii polyglycosidium**: An extract from the Chinese herb Tripterygium wilfordii, known for potent immunosuppressive and anti-inflammatory effects, often used in autoimmune disease treatment in traditional Chinese medicine, and can affect multiple immune pathways. - **Immunosuppressant**: Encompasses drugs such as calcineurin inhibitors (cyclosporine, tacrolimus), antimetabolites (azathioprine, mycophenolate mofetil), mTOR inhibitors (sirolimus), among others, all acting to suppress various pathways in the immune response to prevent transplant rejection or treat autoimmune diseases[2][5][6][8][9]. The combination described does not correspond to any single approved pharmaceutical product but represents a therapeutic strategy involving multiple drug modalities often used in complex immune-mediated conditions or transplantation protocols.